Adalira
info General information
Name Adalira, 40 mg/0.8 mL, solution for subcutaneous administration
INN Adalimumab
Active substance Adalimumab
Pharmacotherapeutic group Immunosuppressants. Tumor necrosis factor-alpha (TNF-α) inhibitors. Adalimumab.
Dosage form Solution for subcutaneous administration.
Packaging
0.8 mL of the product is placed in three-component syringes. The barrel of each syringe is made of colorless neutral glass. One end of the syringe has a fixed stainless steel injection needle protected by a rigid cap. The other end is closed with a plunger, the rod of which is made of polypropylene; the plunger tip has a butyl rubber seal laminated with fluoropolymer. 1 syringe is placed in a blister pack. 2 blister packs are placed in a cardboard box. The box is additionally supplied with 2 alcohol wipes.
Manufacturer Karaganda Pharmaceutical Complex LLP
EU GMP
assignment_turned_in Indications
Adalira is intended for the treatment of the inflammatory diseases described below:
- Rheumatoid arthritis
- Juvenile rheumatoid arthritis
- Polyarticular juvenile idiopathic arthritis
- Enthesitis-related arthritis
- Axial spondyloarthritis
- Ankylosing spondylitis (AS)
- Axial spondyloarthritis without radiographic evidence of AS
- Psoriatic arthritis
- Plaque psoriasis in adults and children
- Hidradenitis suppurativa
- Crohn's disease in adults and children
- Ulcerative colitis in adults and children
- Uveitis in adults and children
